Meeting
2013 ASCO Annual Meeting
Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).
Authors
Michael C. Heinrich
Portland VA Medical Center and Oregon Health and Science University Knight Cancer Institute, Portland, OR
Michael C. Heinrich , Jonathan A. Fletcher , Rana Anjum , Cesar Serrano-Garcia , Sadanand Vodala , Sebastian Bauer , Ajia Town , Meijun Zhu , Yaoyu Ning , Grant Eilers , Diana Griffith , Janice Patterson , Arin McKinley , Frank Y Wang , Andrew P Garner , Victor M. Rivera
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Citation
J Clin Oncol 31, 2013 (suppl; abstr 10509)
DOI
10.1200/jco.2013.31.15_suppl.10509
Abstract #
10509
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
First Author: Cesar Serrano-Garcia
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
First Author: Hao Xu
Poster
2018 ASCO Annual Meeting
Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
First Author: Cesar Serrano